07 Feb 2018
Armis Biopharma to Present at the BIO CEO & Investor Conference

– Presentation with live audio webcast on Monday, February 12 at 3:15 p.m. EST –   Fort Collins, CO (February 7, 2018) Armis Biopharma, Inc. (“Armis” or the “Company”), a late- stage clinical biopharmaceutical company with a growing pipeline of targeted anti-infective therapeutics designed to address antibiotic resistance and healthcare-associated infections, a serious and rapidly […]

Read More
29 Jan 2018
Armis Biopharma Granted QIDP for Lead Product, Ximycin™ for Prophylaxis of Surgical Site Infections in High-Risk Patients Undergoing Non-Emergent Colorectal Surgery

– Ximycin is the first targeted medical therapeutic for the prevention or treatment of surgical site infections –   – Company on track to initiate Phase 3 clinical program in first half of 2018 –   Fort Collins, CO (January 29, 2018) Armis Biopharma, Inc. (“Armis” or the “Company”), a late- stage clinical biopharmaceutical company […]

Read More
09 Jan 2018
Armis Biopharma to Present at Biotech Showcase™ 2018

– Presentation with live audio webcast on Tuesday, January 9th at 2:15 p.m. PST – Fort Collins, CO (January 9, 2018) Armis Biopharma, Inc. (“Armis” or the “Company”), a clinical- stage biopharmaceutical company with a pipeline of targeted anti-infective therapeutics addressing antibiotic resistance and healthcare-associated infections, announced today that Mike Handley, Chief Executive Officer of […]

Read More